# ClinicalIntelPulse Clinical Trial Failure Analysis

> ClinicalIntelPulse Clinical Trial Failure Analysis is a paid API for AI agents from clinicalintelpulse.theaslangroupllc.com, paid per call via x402, $0.2/call, status unknown (last checked 2026-09-14).

Returns a structured failure taxonomy for Phase 2/3 clinical trials in a disease area, including failure reasons, percentages, phase-transition success rates, and design lessons.

## Facts

- Endpoint: GET https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis
- Price: $0.2/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-14
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-clinical-trial-failure-analysis-247be75a
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_XzSaVVUZgIt2I1Ikewopz

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-clinical-trial-failure-analysis-247be75a
```

Example prompt: Give me a failure analysis for Phase 2 and Phase 3 oncology trials — break down the taxonomy of why they failed (wrong target, wrong patient population, endpoint selection, dose, safety issues), with percentages and phase-transition success rates plus key design lessons.

## When to prefer this

Use this endpoint when you need structured, quantitative intelligence on why clinical trials fail in a specific disease area — particularly for informing trial design decisions, go/no-go investment assessments, or competitive risk benchmarking. Prefer this over general pipeline endpoints when the core question is root-cause analysis of trial failure rather than active pipeline status or approval probability.

## Known failure modes

- Unknown or unsupported disease area returns empty or error response
- Overly broad disease category may return low-confidence aggregated data
- Rate limiting or payment failure if USDC balance is insufficient
- Network timeout for complex or data-sparse disease areas

## How this service works

Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors.

## Output

A structured failure taxonomy for Phase 2/3 trials in the queried disease area, including categorized failure reasons (wrong target, patient population mismatch, endpoint failure, dose issues, safety signals), percentage breakdowns across categories, historical phase-transition success rates, and actionable design lessons for drug developers and biotech investors.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "query_summary": {
   "condition": "Alzheimer Disease",
   "trials_analyzed": 78
  },
  "lessons_learned": [
   "Early intervention is critical — treat pre-symptomatic or MCI only",
   "Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)",
   "CDR-SB global score now accepted primary endpoint by FDA (post-2018)",
   "ARIA management protocols must be pre-specified — not post-hoc",
   "Combination approaches (amyloid + tau + neuroinflammation) likely needed"
  ],
  "failure_taxonomy": {
   "wrong_endpoint": {
    "pct": 18,
    "examples": [
     "ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"
    ],
    "key_trials": [
     "Multiple agents 2010-2020"
    ]
   },
   "safety_termination": {
    "pct": 8,
    "examples": [
     "ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"
    ],
    "key_trials": [
     "Aducanumab Phase 3 dose arm"
    ]
   },
   "operational_failures": {
    "pct": 4,
    "examples": [
     "COVID-19 disruption, enrollment failures in rare AD subpopulations"
    ]
   },
   "wrong_patient_population": {
    "pct": 28,
    "examples": [
     "Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"
    ],
    "key_trials": [
     "Bapineuzumab (mild-moderate vs. early)"
    ]
   },
   "wrong_target_or_hypothesis": {
    "pct": 42,
    "examples": [
     "Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"
    ],
    "key_trials": [
     "Solanezumab",
     "Verubecestat",
     "Atabecestat"
    ]
   }
  },
  "what_still_might_fail": [
   "Tau-targeting agents if amyloid clearance alone sufficient",
   "Agents tested in wrong disease stage despite lessons",
   "CNS inflammation approaches without biomarker stratification"
  ],
  "historical_success_rates": {
   "phase2_to_phase3_pct": 31,
   "phase3_to_approval_pct": 11,
   "vs_all_diseases_benchmark": "Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)",
   "overall_clinical_success_pct": 3.4
  },
  "successful_design_principles": "CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration."
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-clinical-trial-failure-analysis-247be75a/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.theaslangroupllc.com](https://www.zero.xyz/host/clinicalintelpulse.theaslangroupllc.com/llms.txt)